Trial was conducted on participants 6 years and older.
Now approved for 2 years and up . Greater than 10 %
chance of adverse reactions.
Median age circa 44
While severe (grade III-IV) aGVHD-free-survival assessed at Day 180 after transplantation was not significantly improved in patients who received Orencia compared to patients who received a placebo (HR 0.55; 95% CI 0.26, 1.18), the OS rate at Day 180 after HSCT was 97% (95% CI: 89%, 99%) for patients who received abatacept compared to 84% (95% CI: 73%, 91%) for patients who received a placebo (HR 0.33; 95% CI: 0.12, 0.93). The moderate-severe (grade II-IV) aGVHD-free survival rate at Day 180 after HSCT was 50% (95% CI: 38%, 61%) for patients who received abatacept compared to 32% (95% CI: 21%, 43%) for patients who received a placebo (HR 0.54; 95% CI: 0.35, 0.83).
Trial was conducted on participants 6 years and older. Now...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
0.105(9.09%) |
Mkt cap ! $1.438B | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.30 | $1.16 | $21.76M | 17.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 98636 | $1.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 600000 | 1 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.27 |
Change
0.105 ( 9.35 %) |
||||
| Open | High | Low | Volume | ||
| $1.17 | $1.30 | $1.16 | 2142493 | ||
| Last updated 15.59pm 28/05/2024 ? | |||||
| MSB (ASX) Chart |